Real-Time PCR System Advances Large Reaction Volume IVD Assay Development and Diagnostic Testing
By LabMedica International staff writers Posted on 02 Feb 2023 |
Amidst the ongoing increase in demand for efficient and flexible IVD real-time PCR systems, a new real-time PCR system advances large reaction volume IVD assay development and diagnostic testing.
Bio-Rad Laboratories (Hercules, CA, USA) has launched the CFX Opus Deepwell Dx Real-Time PCR System that offers accurate and precise quantification with flexibility for reactions up to 125 µl in a 96-well format for quantitative PCR (qPCR) diagnostic assays. This latest addition to the Bio-Rad portfolio of real-time PCR instruments is also available in a 96- and 384-well reaction block format. All systems in the CFX Opus Dx Real-Time PCR family are open platforms that can multiplex up to five targets to enable efficient IVD assay development and diagnostic testing. CFX Opus Dx Real-Time PCR Systems offer easy-to-use desktop management and analysis software with integrated security features for electronic signature, audit, and user control.
The CFX Opus Deepwell Dx Real-Time PCR System is listed with the U.S. Food and Drug Administration (FDA) for in vitro diagnostic (IVD) testing, and has been developed in accordance with the European Union’s regulations for in vitro diagnostic medical devices (EU 2017/746). Bio-Rad will continue to seek regulatory approvals for additional global markets in the coming months.
"With the ongoing increase in demand for efficient and flexible IVD real-time PCR systems, we are pleased to announce the addition of the CFX Opus Deepwell Dx Real-Time PCR System to the CFX Opus family," said Steven Blakely, Senior Director for the Gene Expression Business, Bio-Rad. "The CFX Opus Deepwell Dx Real-Time PCR System continues in the tradition of robust and secure platforms that leverage the long-standing Bio-Rad expertise in genomic tools to serve both research and clinical diagnostic markets."
Related Links:
Bio-Rad Laboratories
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders